Education
About Us
Working with TipRanks
Follow Us
Centessa Pharmaceuticals Plc (CNTA)
:CNTA
CNTA Stock Chart & Stats
$24.33
-$0.91(-5.25%)
At close: 4:00 PM EST
$24.33
-$0.91(-5.25%)
Day’s Range― - ―
52-Week Range$9.60 - $25.31
Previous CloseN/A
Volume658.98K
Average Volume (3M)964.30K
Market Cap
$3.26B
Enterprise Value$1.62B
Total Cash (Recent Filing)$250.72M
Total Debt (Recent Filing)$118.14M
Price to Earnings (P/E)―
Beta1.31
Next Earnings
Nov 17, 2025EPS Estimate
-0.39Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.38
Shares Outstanding134,073,440
10 Day Avg. Volume848,670
30 Day Avg. Volume964,305
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.50
Enterprise Value/Revenue101.80
Enterprise Value/Gross Profit108.20
Enterprise Value/Ebitda-7.58
Forecast
1Y Price Target
$34.50Price Target Upside41.80% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
Bulls Say, Bears Say
Bulls Say
Market OpportunityThere is a large and attractive market opportunity for orexin agonists, with a potential $6-7 billion market that can accommodate multiple assets.
Pipeline DiversificationThe company's diversified orexin agonist pipeline, led by ORX750, shows strong safety and efficacy.
Therapeutic PotentialORX750 has shown significant improvements in sleep latency, indicating potential therapeutic benefits for patients with narcolepsy and idiopathic hypersomnia.
Bears Say
Centessa Pharmaceuticals News
CNTA FAQ
What was Centessa Pharmaceuticals Plc’s price range in the past 12 months?
Centessa Pharmaceuticals Plc lowest stock price was $9.60 and its highest was $25.31 in the past 12 months.
What is Centessa Pharmaceuticals Plc’s market cap?
Centessa Pharmaceuticals Plc’s market cap is $3.26B.
When is Centessa Pharmaceuticals Plc’s upcoming earnings report date?
Centessa Pharmaceuticals Plc’s upcoming earnings report date is Nov 17, 2025 which is in 17 days.
How were Centessa Pharmaceuticals Plc’s earnings last quarter?
Centessa Pharmaceuticals Plc released its earnings results on Aug 12, 2025. The company reported -$0.38 earnings per share for the quarter, missing the consensus estimate of -$0.334 by -$0.046.
Is Centessa Pharmaceuticals Plc overvalued?
According to Wall Street analysts Centessa Pharmaceuticals Plc’s price is currently Undervalued.
Does Centessa Pharmaceuticals Plc pay dividends?
Centessa Pharmaceuticals Plc does not currently pay dividends.
What is Centessa Pharmaceuticals Plc’s EPS estimate?
Centessa Pharmaceuticals Plc’s EPS estimate is -0.39.
How many shares outstanding does Centessa Pharmaceuticals Plc have?
Centessa Pharmaceuticals Plc has 134,073,440 shares outstanding.
What happened to Centessa Pharmaceuticals Plc’s price movement after its last earnings report?
Centessa Pharmaceuticals Plc reported an EPS of -$0.38 in its last earnings report, missing expectations of -$0.334. Following the earnings report the stock price went up 3.01%.
Which hedge fund is a major shareholder of Centessa Pharmaceuticals Plc?
Currently, no hedge funds are holding shares in CNTA
Centessa Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$34.50 (41.80% Upside)
$34.50 (41.80% Upside)
Blogger Sentiment
Bullish
CNTA Sentiment 70%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 3.8M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.6%
Last 30 Days ▲ 4.3%
Last 30 Days ▲ 4.3%
Technicals
SMA
Positive
20 days / 200 days
Momentum
61.23%
12-Months-Change
Fundamentals
Return on Equity
-72.95%
Trailing 12-Months
Asset Growth
23.39%
Trailing 12-Months
Company Description
Centessa Pharmaceuticals Plc
Centessa Pharmaceuticals is a biopharmaceutical company focused on discovering and developing innovative medicines for a wide range of diseases. The company operates in the pharmaceuticals sector, with a portfolio encompassing diverse therapeutic areas such as oncology, hematology, and rare diseases. Centessa leverages a unique 'asset-centric' research model that prioritizes the development of high-potential drug candidates through a network of subsidiary companies, each focused on distinct therapeutic areas.
CNTA Stock 12 Month Forecast
Average Price Target
$34.50
▲(41.80% Upside)
Technical Analysis
Ultragenyx Pharmaceutical
―
Xenon
―
Apellis Pharmaceuticals
―
Scholar Rock Holding
―
Immunovant
―
Ownership Overview
1.16% Insiders
10.34% Mutual Funds
14.89% Other Institutional Investors
73.17% Public Companies and
Individual Investors